Ftse Mib
38.655,09
0,08%
DAX
22.551,43
0,12%
S&P 500
5.954,50
1,59%
NASDAQ
18.847,28
1,63%
Bitcoin
85.240,13
1,03%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lisata Therapeutics Inc (LSTA) Lisata Therapeutics Inc (LSTA) Notizie

LSTA

Lisata Therapeutics (LSTA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LSTA
DataOraFonteTitoloSimboloCompagnia
27/02/202522:05GlobeNewswire Inc.Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateNASDAQ:LSTALisata Therapeutics Inc
20/02/202514:00GlobeNewswire Inc.Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025NASDAQ:LSTALisata Therapeutics Inc
05/02/202514:30GlobeNewswire Inc.Lisata Therapeutics to Present at the 2025 BIO CEO & Investor ConferenceNASDAQ:LSTALisata Therapeutics Inc
23/01/202514:00GlobeNewswire Inc.Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal AdenocarcinomaNASDAQ:LSTALisata Therapeutics Inc
22/01/202514:00GlobeNewswire Inc.Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal AdenocarcinomaNASDAQ:LSTALisata Therapeutics Inc
15/01/202514:30GlobeNewswire Inc.Lisata Therapeutics to Present at the 2025 Sequire Investor SummitNASDAQ:LSTALisata Therapeutics Inc
10/12/202414:30GlobeNewswire Inc.Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX TrialNASDAQ:LSTALisata Therapeutics Inc
03/12/202414:30GlobeNewswire Inc.Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor ImagingNASDAQ:LSTALisata Therapeutics Inc
19/11/202414:30GlobeNewswire Inc.Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’NASDAQ:LSTALisata Therapeutics Inc
12/11/202422:05GlobeNewswire Inc.Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LSTALisata Therapeutics Inc
06/11/202415:23GlobeNewswire Inc.Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research CollaborationNASDAQ:LSTALisata Therapeutics Inc
06/11/202414:30GlobeNewswire Inc.Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024NASDAQ:LSTALisata Therapeutics Inc
31/10/202413:30GlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
28/10/202413:30GlobeNewswire Inc.Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of EndometriosisNASDAQ:LSTALisata Therapeutics Inc
03/10/202414:00GlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
17/09/202414:00GlobeNewswire Inc.Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER TrialNASDAQ:LSTALisata Therapeutics Inc
09/09/202414:00GlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
05/09/202414:00GlobeNewswire Inc.Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of CholangiocarcinomaNASDAQ:LSTALisata Therapeutics Inc
12/08/202422:05GlobeNewswire Inc.Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LSTALisata Therapeutics Inc
05/08/202414:00GlobeNewswire Inc.Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024NASDAQ:LSTALisata Therapeutics Inc
18/07/202414:00GlobeNewswire Inc.Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer TherapyNASDAQ:LSTALisata Therapeutics Inc
16/07/202414:00GlobeNewswire Inc.Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line CholangiocarcinomaNASDAQ:LSTALisata Therapeutics Inc
10/07/202414:00GlobeNewswire Inc.Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical ModelNASDAQ:LSTALisata Therapeutics Inc
13/06/202414:30GlobeNewswire Inc.Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX TrialNASDAQ:LSTALisata Therapeutics Inc
28/05/202414:30GlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
20/05/202414:30GlobeNewswire Inc.Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic CancerNASDAQ:LSTALisata Therapeutics Inc
10/05/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LSTALisata Therapeutics Inc
09/05/202422:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LSTALisata Therapeutics Inc
09/05/202422:05GlobeNewswire Inc.Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LSTALisata Therapeutics Inc
08/05/202414:00GlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LSTA

La tua Cronologia

BIT
ENI
Eni
BIT
UCG
Unicredit
BIT
NEXI
Nexi S.p.A
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
LDO
Leonardo
BIT
PRY
Prysmian
BIT
ENEL
Enel
BIT
RACE
Ferrari NV
BIT
STMMI
ST Microelectronics
BIT
SPM
Saipem
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
BIT
MONC
Moncler
BIT
BAMI
Banco BPM
BIT
FCT
Fincantieri
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci